TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03244163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spyglass DS cholangioscope
Description: The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BML
Description: Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
Study: NCT04045678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003 ( Rotigotine, extended-release microspheres)
Description: Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, extended-release microspheres
Description: Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks.
Study: NCT04157595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive Genetic Carrier Screening
Description: Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
Study: NCT03030079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Electrical Stimulation Regimen
Description: The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
Study: NCT02665208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapies
Description: a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message Intervention (TMI)
Study: NCT02028988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Study: NCT01452464

Intervention type: BIOLOGICAL
Intervention: MenACWY-CRM
Description: MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
Study: NCT04636333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Description: Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Description: Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Description: Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Study: NCT02680639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP Synchrony ventilator
Description: The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP Synchrony ventilator
Description: The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP Synchrony ventilator
Description: The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP Synchrony ventilator
Description: The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
Study: NCT00747435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic System
Description: Combination of a cochlear implant and a hearing aid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic System
Description: Combination of a cochlear implant and a hearing aid
Study: NCT03027895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS)
Description: Endoscopic Ultrasound-guided Drainage of WON with LAMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double pigtail plastic stent (DPPS)
Description: Endoscopic Ultrasound-guided Drainage of WON with DPPS
Study: NCT02813603

Intervention type: PROCEDURE
Intervention: EBUS
Description: 19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.

Intervention type: PROCEDURE
Intervention: EBUS
Description: 19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
Study: NCT02113956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guy2Guy (G2G)
Description: G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active.
Study: NCT00604461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, Bevacizumab and Pemetrexed
Description: Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
Study: NCT04636333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Description: Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Study: NCT03662009

Intervention type: OTHER
Intervention: multilimb dual task
Description: control of arm and foot in two attentional contexts of simulated driving

Intervention type: OTHER
Intervention: multilimb dual task
Description: control of arm and foot in two attentional contexts of simulated driving
Study: NCT04429672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Right to your Sexual Health
Description: which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friendly sexual health services and reproductive for adolescents
Description: consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
Study: NCT03242863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food proportionality
Description: Proportions of high and low energy dense foods manipulated
Study: NCT04636333

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Description: Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Description: Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 14 #High-dose group#
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Study: NCT04192461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth guided immediate implant placement
Description: The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
Study: NCT00372840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study: NCT00837343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate tablet (Seroquel)
Description: Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
Study: NCT03725813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centred inpatient care
Description: The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention.
Study: NCT02412046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle biopsy
Study: NCT00372840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT02854527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: 10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
Study: NCT00098618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03744624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Description: Laparoscopic liver resection for oncological purposes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic liver resection
Description: Laparoscopic liver resection for oncological purposes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing model
Description: Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
Study: NCT00643812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Installation of gun locker in household
Description: Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Installation of gun locker in household
Description: Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline.
Study: NCT03189992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bushen-Jianpi Dedoction
Description: A traditional chinese medicine prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bushen-Jianpi Dedoction
Description: A traditional chinese medicine prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinobufotalin injection
Description: an effective Chinese preparation to treat malignant tumor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cinobufotalin injection
Description: an effective Chinese preparation to treat malignant tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinobufotalin injection
Description: an effective Chinese preparation to treat malignant tumor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cinobufotalin injection
Description: an effective Chinese preparation to treat malignant tumor.
Study: NCT03381170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
Study: NCT00978614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)
Study: NCT03905694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered by subcutaneous (SC) injection.
Study: NCT01749423

Intervention type: BIOLOGICAL
Intervention: OnabotulinumtoxinA
Description: Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Study: NCT00704132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate
Description: Sitagliptin tablet 100 mg, administered once daily before the morning meal.
Study: NCT02412046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle biopsy
Study: NCT02253485

Intervention type: DRUG
Intervention: telbivudine
Description: in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV.
Study: NCT03242863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food proportionality
Description: Proportions of high and low energy dense foods manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food proportionality
Description: Proportions of high and low energy dense foods manipulated
Study: NCT00704132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Matching placebo tablet, administered once daily before the morning meal.
Study: NCT00504751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone, ifosfamide
Description: VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5
Study: NCT01969435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan HCl (propylene glycol-free)
Study: NCT03207594

Intervention type: OTHER
Intervention: Survey
Description: Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.

Intervention type: OTHER
Intervention: Saliva sample
Description: Subjects will have saliva collected by a member of the study team using a cotton swab.

Intervention type: OTHER
Intervention: Smoking Status questions
Description: Subjects will be asked to complete an assessment asking questions about his/her current smoking status
Study: NCT06173908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cell treatment
Description: Autologous epidermal basal cells were used to repair nonhealing postoperative wound

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control treatment
Description: anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
Study: NCT01297725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blunt right, sharp left
Description: Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blunt left, sharp right
Description: Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
Study: NCT01161537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet.
Study: NCT03764306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endarterectomy carotid artery
Description: Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
Study: NCT03853525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one side of the inguinal region.
Study: NCT02215135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
Study: NCT01673620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/loratadine 10 mg
Description: Montelukast 10 mg/loratadine 10 mg tablet administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet administered once daily
Study: NCT02843828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait rehabilitation with Samsung Hip Assist v1
Description: Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait rehabilitation without Samsung Hip Assist v1
Description: Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session